/
Other
Toxicity
47
Pipeline Programs↗
30
Active Trials↗
27
Companies Involved↗
Toxicity is a moderately active landscape with 47 programs across 27 companies. The most active players are Bayer. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical35
Phase 26
Phase 35
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
36 of 43 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 43 classified programs, each share of the total. Modality classified for 100% of 47 pipeline programs.
Analysis
Trial Status
182
clinical trials
Completed88 · 48%
Unknown status40 · 22%
Recruiting17 · 9%
Terminated14 · 8%
Active, not recruiting7 · 4%
Not yet recruiting6 · 3%
Other10 · 5%
Clinical Trials
Trial Activity
182 trials
Ofloxacin Concentration-toxicity Relationship in the Elderly
Recruiting·—·N/A·NCT04496024·110 enrolled
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
Recruiting·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT07018622·46 enrolled
Oxygen Toxicity: Mechanisms in Humans
Recruiting·—·N/A·NCT05761756·62 enrolled
Pantoprazole in Cisplatin Nephrotoxicity
Recruiting·—·Phase 3·NCT04217512·60 enrolled
Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
Recruiting·—·N/A·NCT06765252·80 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)